AAO 2023: Three technologies from this year's new launches at Bausch + Lomb

Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Anthony Wallace, BS, MBA:

Hi, I'm Anthony Wallace, vice president and general manager of the surgical business at Bausch and Lomb North America. We're really excited to be here with all of you at the American Academy of Ophthalmology. Bausch and Lomb has just recently launched three new technologies within the US marketplace.

The first is enVista Aspire monofocal and toric IOLs, with intermediate optimised optics. The second is our eyeTELLIGENCE surgical planning software. And the third is our SeeNa ophthalmic diagnostic device.

The enVista Aspire features novel optics that allow for a broader range of vision, which makes it a really compelling option for many patients who interact with digital devices on a daily basis. And surgeons are very, very comfortable and familiar with the enVista platform. More than five-and-a-half million enVista lenses have been implanted worldwide. Surgeons are very comfortable with the key benefits. So things like glistening free optics, stable flex material that allows for smooth and efficient unfolding in the bag. They're familiar with the stable or the the SureEdge design on the haptics to ensure or minimise PCO. And really, the distinction of being the only toric platform that allows for correction of astigmatism down to 1 diopter at the corneal plane.

The new eyeTELLIGENCE software simplifies the complex and time-consuming surgical planning process. It enables a smooth and secure flow of information between devices without the need for additional folders, additional material printouts, and so forth. This will really simplify that, that process and enable a full integration of the technology. It integrates fully with the EMR platforms as well as the diagnostic device systems. In fact, our new SeeNa is a perfect example. SeeNa captures 9 key measurements in 1 easy step for refractive cataract patients, and it fully integrates with our eyeTELLIGENCE surgical planning software.

On the pharmaceutical side, we recently launched MIEBO, the first and only FDA-approved eyedrop that directly targets tear evaporation. In addition to MIEBO, we've also acquired XIIDRA, fully building out our dry eye portfolio. So we're really excited about some of these new advancements, these new introductions into the market and look forward to continuing to partner with each of you and helping patients see better to live better. Thank you.